New Publication alert

New paper led by Dr Peter May and colleagues and published in BMC Health Services Research examines the cost-effectiveness of repurposing mirtazapine for severe breathlessness in advanced respiratory disease. Using data from the multinational BETTER-B trial, the study found that mirtazapine did not improve quality of life and increased overall costs — with only a 1–2% chance of being cost-effective.

The work has a clear message: even low-cost, familiar drugs can offer poor value when repurposed without strong evidence.

Read more:

https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-025-13605-9